Our technology is a first in class treatment for rosacea which one of the largest unmet needs in dermatology. Our product ACU-D1 has the potential to transform the current treatment paradigm for rosacea and drive signifant company value. Our compound has an established safety profile and strong preclinical evidence of efficacy. We have secured adequate funding to complete IND enabling toxicology and phase 1-2 clinical studies. Recent exits have established a strong valuation potential for the company.
Imagine having no pain when the dentist gives you a shot or when you dermatologist numbs you before removing a mole. If you are a healthcare provider, picture the patient getting numb every time and within a few minutes instead of 15 minutes. If you are a health system, think about not worrying about the cross contamination of vials. At Anutra Medical, we have developed a simple solution to an age-old problem. We have designed a closed-mixing and dispensing system along with an innovative syringe that enhances the patient experience through eliminating pain as well as increases efficiency for healthcare providers, all while improving patient safety.
Avancen provides the first oral patient controlled analgesia device for pain management in healthcare facilities to come to market. The device called the MOD for Medication On Demand is a Wi-Fi device secured at the patient bedside and programmed via its enterprise software to collect patient pain score data and self-administration data of oral pain medication delivery that can be integrated into the electronic health record (EHR) or used as a standalone database device. The patient is able to access the medication using a Radio Frequency (RFID) bracelet registered to the device for their exclusive use. The MOD is becoming the evidenced based standard of care for the delivery of as needed oral pain medication in acute care and post-acute care facilities.
BioMedomics, Inc. is a point-of-care (POC) diagnostics company focused on unique, disease-specific tests and highly- advanced quantitative detection platforms. The Company has successfully developed and marketed 3 novel tests for hemoglobinopathies: Sickle SCAN®, alpha-Thal SCAN®, and Hemo SCAN®. We also recently received regulatory approval, and are working towards product launch for a novel POC quantitative test for hemoglobin S (HbS) which is used in the treatment of Sickle Cell Disease. Additionally, quantitative POC tests for TSH, testosterone, vitamin D and troponin based on our patented high sensitivity Time Resolved diagnostics platform and a rapid POC test for beta-thalassemia, are also under development.
More than a million Americans get sepsis - a bloodstream infection – every year. A quarter million die. The accompanying healthcare costs are astronomical. A major barrier for better care is that it takes days to identify the specific pathogen causing the infection, so treatment is delayed. iCubate is an innovative molecular diagnostic company that will provide solutions to vital clinical problems – including but not exclusive to sepsis - for a variety of research challenges. We provide a patented mutiplex polymerase chain reaction (mPCR) technology, an integrated and automated platform, and a product line for infectious disease diagnostics and research applications. We offer products to detect multiple disease causing pathogens at one time using only minutes of hands on time by lab technicians, with a sample to answer turn around time of hours rather than days – all in a closed system that eliminates risk of contamination. Our initial focus is the clinical laboratory setting – including laboratory developed tests (LDTs) – providing accurate and cost saving diagnostics. That is the just the beginning. The iCubate system has the flexibility to expand into multiple markets including food safety and agriculture.
OBMedical has developed LABORVIEW®, an FDA-cleared external sensor system that provides fetal monitoring in patients of all sizes. LABORVIEW® is a simple accessory that can be plugged into one of the 28,000 existing ultrasound based fetal monitors that already interfaced to hospital information systems. LaborView displays both fetal heart rate, maternal heart rate and contractions allowing access to an $800 million dollar annual worldwide market for the high margin disposable alone.